Journal article
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials
Abstract
AIMS: Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV) events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism. Recently, two large randomized clinical trials evaluated the efficacy and safety of low-dose rivaroxaban twice daily plus aspirin in stable PAD outpatients and those immediately after peripheral revascularization. We sought to determine if the effects of low-dose …
Authors
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E
Journal
European Journal of Preventive Cardiology, Vol. 29, No. 5, pp. e181–e189
Publisher
Oxford University Press (OUP)
Publication Date
May 5, 2022
DOI
10.1093/eurjpc/zwab128
ISSN
2047-4873